News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR



7/18/2011 8:02:26 AM

Regensburg, Germany, July 18, 2011 / B3C newswire / - Lophius Biosciences, a leading developer of novel, innovative T-cell-based diagnostic test systems, announced today closing of an additional financing round totaling 1.4 million EUR. All current financial investors, such as S-Refit, High-Tech Gründerfonds (HTGF) as well as Bayernkapital participated in this financing round. The funds will be used for the market introduction of the T-Track© CMV/EBV tests in the field of transplantation, for further development of a diagnostic test for the differential diagnosis of tuberculosis, as well as for the new development of a novel, blood-based multiple sclerosis test.

“We are very pleased to have been able to conclude this financing round with our existing investors in such a short time. Subsequent to the successful establishment of the company over the past year and the imminent conclusion of the test developments for our patented T-Track © CMV/EBV Tests, these new financial resources allow us to prepare for market entry of these tests from the beginning of 2012 with an effective team. Beyond this, we will now intensify the development of additional innovative diagnostic tests based on our patented technology platforms,” said Dr. Michael Lutz, CEO of Lophius Biosciences.

“With the aid of the financing round in the precious year Lophius Biosciences has been able to develop from an essentially academic research company into a small, highly innovative and fully integrated diagnostic company within a very short timeframe. We are absolutely convinced that the Lophius’ technologies and the products have a great potential to provide patients with large diagnostic benefits in our disease areas,” amended Bertram Gilka-Bötzow of S-Refit, Lophius Biosciences’ lead investor.

About Lophius Biosciences

Lophius Biosciences GmbH develops and markets innovative T-cell-based test systems for diagnostics and possible therapy control in the fields of transplantation, infection, and autoimmune diseases.

Contact:

Kerstin Maier

Phone: +49 941 6309 1972

E-Mail: kerstin.maier@lophius.de

www.lophius.de


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES